INTERWEST VENTURE MANAGEMENT CO - Q3 2021 holdings

$241 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 10 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 20.0% .

 Value Shares↓ Weighting
PMVP SellPMV PHARMACEUTICALS INC$115,323,000
-32.1%
3,869,911
-22.1%
47.76%
-10.8%
AI  C3.AIcl a$40,166,000
-25.9%
866,7740.0%16.64%
-2.7%
REAL  THE REALREAL$31,027,000
-33.3%
2,354,0800.0%12.85%
-12.5%
NewSERA PROGNOSTICS$26,844,0002,416,241
+100.0%
11.12%
GKOS BuyGLAUKOS CORP$16,872,000
-42.6%
350,264
+1.1%
6.99%
-24.6%
EIGR  EIGER BIOPHARMACEUTICALS INC$5,110,000
-21.6%
764,9180.0%2.12%
+2.9%
AGTC  APPLIED GENETIC TECHNOL CORP$4,228,000
-23.0%
1,404,5150.0%1.75%
+1.0%
VERO  VENUS CONCEPT INC$1,653,000
-19.3%
658,6570.0%0.68%
+6.0%
XENE  XENON PHARMACEUTICALS INC$127,000
-14.2%
8,2930.0%0.05%
+12.8%
DARE BuyDARE BIOSCIENCE INC$104,000
+9.5%
62,065
+23.2%
0.04%
+43.3%
CDTX ExitCIDARA THERAPEUTICS INC$0-1,356,813
-100.0%
-0.86%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-10-19
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
GLAUKOS CORP28Q3 202333.0%
EIGER BIOPHARMACEUTICALS INC24Q3 202217.7%
APPLIED GENETIC TECHNOL CORP24Q3 20226.7%
XENON PHARMACEUTICALS INC20Q3 20210.6%
CIDARA THERAPEUTICS INC19Q2 20214.5%
THE REALREAL18Q3 202362.6%
KALVISTA PHARMACEUTICALS INC17Q4 202010.8%
DARE BIOSCIENCE INC16Q3 20230.3%
MACROGENICS INC14Q1 202019.2%
PMV PHARMACEUTICALS INC13Q3 202367.5%

View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.

Latest filings
TypeFiled
1442024-02-27
13F-HR2023-10-20
13F-HR2023-07-21
13F-HR2023-04-27
13F-HR2023-01-31
13F-HR2022-10-25
13F-HR2022-08-02
13F-HR2022-04-13
13F-HR2022-01-25
13F-HR2021-10-19

View INTERWEST VENTURE MANAGEMENT CO's complete filings history.

Compare quarters

Export INTERWEST VENTURE MANAGEMENT CO's holdings